No, Astec LifeSciences is not a debt-free company. The enterprise carries working capital loans and term debt obligations on its balance sheet—totaling roughly ₹448 crore to ₹48 million USD equivalent—utilized to fund manufacturing plant expansions, R&D investments like the Adi Godrej Center for Chemical Research, and working capital requirements. Consequently, its debt-to-equity ratio fluctuates, requiring active management by the corporate finance team to optimize capital structures.